<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="case-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Psoriasis (Auckl)</journal-id><journal-id journal-id-type="iso-abbrev">Psoriasis (Auckl)</journal-id><journal-id journal-id-type="pmc-domain-id">3311</journal-id><journal-id journal-id-type="pmc-domain">psoriasis</journal-id><journal-id journal-id-type="publisher-id">ptt</journal-id><journal-title-group><journal-title>Psoriasis: Targets and Therapy</journal-title></journal-title-group><issn pub-type="epub">2230-326X</issn><publisher><publisher-name>Dove Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12476186</article-id><article-id pub-id-type="pmcid-ver">PMC12476186.1</article-id><article-id pub-id-type="pmcaid">12476186</article-id><article-id pub-id-type="pmcaiid">12476186</article-id><article-id pub-id-type="doi">10.2147/PTT.S552600</article-id><article-id pub-id-type="publisher-id">552600</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Vunakizumab for Treatment of Acrodermatitis Continua of Hallopeau: A Case Report and Literature Review</article-title><alt-title alt-title-type="running-authors">Yao et al</alt-title><alt-title alt-title-type="running-title">Yao et al</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yao</surname><given-names initials="Y">Yi</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Ma</surname><given-names initials="Y">Yingming</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhong</surname><given-names initials="H">Huajie</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="F">Feiying</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="J">Jiling</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="Y">Yuan</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="S">Shunli</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>1</label><institution>Department of Dermatology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University</institution>, <addr-line>Huzhou</addr-line>, <country>People&#8217;s Republic of China</country></aff><aff id="aff0002"><label>2</label><institution>Department of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University</institution>, <addr-line>Huzhou</addr-line>, <country>People&#8217;s Republic of China</country></aff><aff id="aff0003"><label>3</label><institution>Department of Dermatology, Affiliated Huzhou Hospital, Zhejiang University School of Medicine</institution>, <addr-line>Hangzhou</addr-line>, <country>People&#8217;s Republic of China</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Shunli Tang, <institution>Department of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University</institution>, <addr-line>No. 1558, Sanhuan North Road</addr-line>, <addr-line>Huzhou</addr-line>, <addr-line>313000</addr-line>, <country>People&#8217;s Republic of China</country>, <phone content-type="general">Tel +86-572-2555321</phone>, Email tangshunli@zju.edu.cn</corresp><fn id="ft0001"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478864</issue-id><fpage>471</fpage><lpage>478</lpage><history><date date-type="received"><day>11</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>06</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 21:25:17.150"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Yao et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Yao et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#8211; Non Commercial (unported, v4.0) License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ptt-15-471.pdf"/><abstract><title>Abstract</title><p>Acrodermatitis continua of Hallopeau (ACH) is a rare pustular psoriasis subtype, characterized by recurrent sterile pustules on digits, progressive nail deformation and atrophy. ACH is often refractory to different therapeutic modalities, presenting challenges in clinical practice. Emerging evidence indicates that elevated IL-17 levels modulate keratinocyte proliferation and immune cell infiltration, contributing to ACH pathogenesis and representing a promising therapeutic target. Herein, we presented a case of ACH successfully treated with vunakizumab, China&#8217;s first self-developed anti-IL-17A monoclonal antibody, and reviewed publications reporting IL-17 targeted therapies for ACH, highlighting the potential benefit of IL-17 targeted therapy in ACH management.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>acrodermatitis continua of hallopeau</kwd><kwd>pustular psoriasis</kwd><kwd>interleukin-17</kwd><kwd>vunakizumab</kwd></kwd-group><counts><fig-count count="1"/><table-count count="2"/><ref-count count="35"/><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Acrodermatitis continua of Hallopeau (ACH) is a rare and debilitating pustular psoriasis (PP), characterized by recurrent sterile pustules on digits, progressive destruction of nail apparatus, with or without underlying bone erosions. ACH treatment is challenging, since no standard guidelines have been reported and traditional psoriasis therapies, ie phototherapy, topical corticosteroids and calcineurin inhibitors, systemic methotrexate, acitretin, ciclosporin, exhibit poor efficacy.<xref rid="cit0001" ref-type="bibr">1</xref> Biological agents targeting tumor necrosis factor, interleukin (IL)-17, IL-23, and IL-36&#160;have been evaluated for off-label therapeutic use in ACH.<xref rid="cit0002" ref-type="bibr">2</xref> Herein, we reported a case of ACH successfully treated with vunakizumab and achieved satisfactory response.</p></sec><sec id="s0002"><title>Case Presentation</title><p>A 76-year-old woman presented with a 2-year history of painful erythema and pustules on fingertips (Numeric Scale Score (NRS): 10), along with onychodystrophy. She was previously diagnosed with onychomycosis and perionychial eczema and was treated with systemic antifungal and topical corticosteroids. However, her condition did not improve and the lesions continued to progress. She was otherwise healthy and denied history of trauma or psoriasis. Physical examination revealed erythema, desquamation, and blood crusts on distal fingers, hyperkeratosis, detachment and deformation on nails (<xref rid="f0001" ref-type="fig">Figure 1A</xref>). A skin biopsy showed neutrophil aggregation in stratum corneum, hyperkeratosis, parakeratosis, diminished granular layer, and acanthosis, consistent with psoriasis (<xref rid="f0001" ref-type="fig">Figure 1B</xref>). The patient was thus diagnosed with ACH. Treatment with vunakizumab was initiated, with a regimen of 240 mg subcutaneous injection at weeks 0, 2, and 4, and every 4&#160;weeks thereafter. The pain completely resolved after 1&#160;week (NRS:0), the skin lesions began to improve at 2&#160;weeks and significantly subsided at 10&#160;weeks, along with partial nail regrowth (<xref rid="f0001" ref-type="fig">Figure 1C</xref>). No adverse reactions were observed during treatment.<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>(<bold>A</bold>) Initial clinical presentation showing erythema, desquamation, and blood crusts on distal digits, hyperkeratosis, detachment and deformation on nails. (<bold>B</bold>) Histopathologic examination of digital biopsy showing neutrophil aggregation in stratum corneum, hyperkeratosis, parakeratosis, diminished granular layer, and acanthosis (original magnification, &#215;200). (<bold>C</bold>) Clinical photographs at week 10 showing faded digital erythema and partial nail regrowth.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="PTT-15-471-g0001.jpg"/></fig></p></sec><sec id="s0003"><title>Discussion</title><p>ACH, a rare form of PP, typically manifests as chronic, recurrent, inflammatory pustular eruptions of digits and nail apparatus that may lead to onchodystrophy, anonychia, and osteolysis. Although commonly confined to digits, ACH can also extend proximally, even evolving into generalized PP.<xref rid="cit0001" ref-type="bibr">1</xref></p><p>Although PP pathogenesis remains incompletely understood, IL-17 appears to play a significant role.<xref rid="cit0003" ref-type="bibr">3</xref> Serum and cutaneous levels of IL-17 were higher in patients with PP than in healthy controls. Co-localization analyses suggested infiltrated neutrophils as important source of IL-17, which can induce IL-36&#160;secretion, together inducing keratinocyte hyperproliferation and immune cell infiltration, driving psoriasis progression.<xref rid="cit0003" ref-type="bibr">3</xref> Therefore, IL-17 is considered a promising therapeutic target in PP.</p><p>Vunakizumab is China&#8217;s first approved, domestically developed, recombinant anti-IL-17A monoclonal antibody for the treatment of adult patients with moderate-to-severe plaque psoriasis, based on its promising premarketing clinical profile demonstrating high efficacy and favorable tolerability.<xref rid="cit0004" ref-type="bibr">4&#8211;6</xref> Approximately 70% of patients achieved PASI 90 at week 12 and maintained clinical improvement through week 52, demonstrating that its efficacy was comparable to other IL-17A inhibitors, eg secukinumab and ixekizumab, while offering a longer 4-week dosing interval.<xref rid="cit0007" ref-type="bibr">7</xref> Here, we present the first case of ACH successfully treated with vunakizumab. Digital pain resolved within 1&#160;week after treatment initiation, and skin lesions improved by week 2. No adverse events were observed during treatment.</p><p>We also reviewed published literature reporting IL-17-targeted therapy for ACH. As of January 2025, 28 articles that included 79 patients with ACH tried IL-17-targeted therapy, including ixekizumab, secukinumab, bimekizumab, and brodalumab (<xref rid="t0001" ref-type="table">Table 1</xref>). Among them, 68 patients achieved disease relief with treatment and the other 11 patients exhibited poor response. Notably, despite an initial poor response to IL-17-targeted therapy, some patients achieved symptomatic relief and improvement after switching to another IL-17 inhibitor or other biologics, indicating the heterogeneity of ACH.<xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0009" ref-type="bibr">9</xref> Although IL-17-targeted therapy was considered safe, several adverse events were reported, with 1 patient discontinuing treatment,<xref rid="cit0010" ref-type="bibr">10</xref> highlighting the importance of monitoring therapeutic efficacy and adverse reactions, avoiding futile treatment, and preventing severe adverse events.
<table-wrap position="float" id="t0001" orientation="landscape"><label>Table 1</label><caption><p>Interleukin-17 Inhibitors for the Treatment of Acrodermatitis Continua of Hallopeau</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Reference</th><th rowspan="1" colspan="1">Number</th><th rowspan="1" colspan="1">Disease Duration</th><th rowspan="1" colspan="1">Psoriatic Symptom</th><th rowspan="1" colspan="1">Other Comorbidity</th><th rowspan="1" colspan="1">Laboratory Examination<sup>#</sup></th><th rowspan="1" colspan="1">Previous Treatment</th><th rowspan="1" colspan="1">Response to Therapy</th><th rowspan="1" colspan="1">Adverse Event</th></tr></thead><tbody><tr><td colspan="9" rowspan="1"><bold>Successful experience</bold></td></tr><tr><td colspan="9" rowspan="1"><bold>Ixekizumab: IL-17A</bold></td></tr><tr><td rowspan="1" colspan="1">Pilz<xref rid="cit0011" ref-type="bibr">11</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2 years</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Topical therapy, systemic anti-bacterial and anti-fungal therapy</td><td rowspan="1" colspan="1">Acral inflammation resolved, nails regrew, pain relieved after 3 months</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Miller<xref rid="cit0012" ref-type="bibr">12</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&gt;3 ears</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Topical therapy, cyclosporine, apremilast, adalimumab</td><td rowspan="1" colspan="1">Skin and nail lesions began to improve within 2&#160;weeks, and almost completely resolved after 10&#160;weeks</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Battista<xref rid="cit0013" ref-type="bibr">13</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2 years</td><td rowspan="1" colspan="1">Psoriatic arthritis</td><td rowspan="1" colspan="1">Latent HBV infection</td><td rowspan="1" colspan="1">Enthesitis</td><td rowspan="1" colspan="1">Topical and systemic antibiotics</td><td rowspan="1" colspan="1">Lesions improved and pain disappeared after 4&#160;weeks, and skin and nail lesions completely resolved after 7 months</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Gargiulo<xref rid="cit0014" ref-type="bibr">14</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Psoriasis (unknown type)<break/>Psoriatic arthritis</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Skin lesions completely resolved, and nail lesions improved after 36&#160;weeks</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Xia<xref rid="cit0015" ref-type="bibr">15</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2 years</td><td rowspan="1" colspan="1">Inverse psoriasis1</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Acitretin, etanercept</td><td rowspan="1" colspan="1">Skin lesions over the body completely resolved after 8&#160;weeks<break/>Digital and nail lesions improved after 24&#160;weeks, completely resolved after 32&#160;weeks, and maintained resolution</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Guerra<xref rid="cit0016" ref-type="bibr">16</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Systemic anti-biotical and anti-fungal therapy</td><td rowspan="1" colspan="1">Skin and nail lesions completely resolved after 6 months</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Chularojanamontri<xref rid="cit0017" ref-type="bibr">17</xref></td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Symptoms improved in all patients, with 3 experience symptoms clearance</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Yuan<xref rid="cit0018" ref-type="bibr">18</xref></td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">&gt;1 year</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Symptoms improved in all patients, with 8 experience excellent response<sup>a</sup></td><td rowspan="1" colspan="1">4 adverse events<sup>b</sup></td></tr><tr><td colspan="9" rowspan="1"><bold>Secukinumab: IL-17A</bold></td></tr><tr><td rowspan="1" colspan="1">Baron<xref rid="cit0019" ref-type="bibr">19</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Approximately 10 years</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Erosive oral mucositis</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Topical and systemic therapy, including anti-viral, anti-bacterial, anti-fungal, anti-inflammatory, immunomodulatory, and biological agents (apremilast)</td><td rowspan="1" colspan="1">Finger changes disappeared, pain relieved, and neurologic sensory recovered in approximately 5 days</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Muggli<xref rid="cit0020" ref-type="bibr">20</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2 years</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Anti-biotic therapy, topical therapy, UV-B phototherapy, acitretin</td><td rowspan="1" colspan="1">Digital inflammation completely resolved, fingernails begun regrow, pain relieved after 6&#160;weeks</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Balestri<xref rid="cit0021" ref-type="bibr">21</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">8 years</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Acroosteolysis and erosion at phalanxs</td><td rowspan="1" colspan="1">Topical therapy, acitretin</td><td rowspan="1" colspan="1">Skin and nail lesions improved after 4&#160;weeks, lesions further improved and nails regrew after 10 months</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Khosravi-Hafshejani<xref rid="cit0022" ref-type="bibr">22</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1 year</td><td rowspan="1" colspan="1">Psoriatic arthritis</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Distal phalanges splaying, dactylitis</td><td rowspan="1" colspan="1">Acitretin</td><td rowspan="1" colspan="1">Skin and nail changes almost completely resolved, joint tenderness and swelling relieved within 4 months, and full and sustained remission maintained over 2 years</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Galluzzo<xref rid="cit0023" ref-type="bibr">23</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1 year</td><td rowspan="1" colspan="1">Psoriatic arthritis</td><td rowspan="1" colspan="1">Lactose intolerance</td><td rowspan="1" colspan="1">Enthesitis with effusion at fingertips</td><td rowspan="1" colspan="1">Topical therapy, systemic antibiotics, acitretin</td><td rowspan="1" colspan="1">Nail lesions markedly improved from 8&#160;weeks, and exhibited almost complete resolution after 52&#160;weeks<break/>Arthritis disappeared after 40&#160;weeks</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Smirnova<xref rid="cit0024" ref-type="bibr">24</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4 years</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Phototherapy, methotrexate, retinoids, apremilast, infliximab</td><td rowspan="1" colspan="1">Symptoms improved after 2&#160;weeks, nails regrew after 3&#160;weeks</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Kromer<xref rid="cit0010" ref-type="bibr">10</xref></td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">No response to treatment in 3 patients, partial improvement in 4 patients<sup>c,d</sup></td><td rowspan="1" colspan="1">2 adverse events, with 1 leading to treatment discontinuation</td></tr><tr><td rowspan="1" colspan="1">Chularojanamontri<xref rid="cit0017" ref-type="bibr">17</xref></td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Symptoms improved in both patients, with 1 experience symptoms clearance</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Yuan<xref rid="cit0018" ref-type="bibr">18</xref></td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">&gt;1 year</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Symptoms improved in all patients, with 3 experience excellent response</td><td rowspan="1" colspan="1">3 adverse events<sup>b</sup></td></tr><tr><td colspan="9" rowspan="1"><bold>Bimekizumab: IL-17A, IL-17F</bold></td></tr><tr><td rowspan="1" colspan="1">Cirone<xref rid="cit0025" ref-type="bibr">25</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">8 years</td><td rowspan="1" colspan="1">Plaque and inverse psoriasis</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Topical therapy, systemic antibiotics, methotrexate, acitretin</td><td rowspan="1" colspan="1">Nail lesions improved and thumbnails regrew after 2 months</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Passeron<xref rid="cit0008" ref-type="bibr">8</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Palmoplantar pustulosis, psoriatic arthritis</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Methotrexate, adalimumab, ixekizumab ustekinumab</td><td rowspan="1" colspan="1">Nail symptoms improved, joint pain and skin lesions disappeared after 9 months</td><td rowspan="1" colspan="1">Transient oral and genital candidiasis</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Palmoplantar pustulosis&#160;</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Methotrexate, acitretin</td><td rowspan="1" colspan="1">Nail symptoms improved, and skin lesions disappeared after 6 months</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Palmoplantar pustulosis,<break/>psoriatic arthritis</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Ixekizumab</td><td rowspan="1" colspan="1">Skin and nail symptoms improved after 7 months</td><td rowspan="1" colspan="1">Transient oral candidiasis</td></tr><tr><td rowspan="1" colspan="1">Yoshikawa<xref rid="cit0026" ref-type="bibr">26</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1 year</td><td rowspan="1" colspan="1">Psoriatic arthritis</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Enthesitis at ankle and knee joint<break/>IL-36RN genetic mutation (c.28T&gt;C)</td><td rowspan="1" colspan="1">Topical therapy, etretinate, apremilast, guselkumab</td><td rowspan="1" colspan="1">Skin and nail lesions improved after 2&#160;weeks, and almost disappeared after 4 months</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Garc&#237;a-Rodr&#237;guez<xref rid="cit0027" ref-type="bibr">27</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1 years</td><td rowspan="1" colspan="1">Plaque psoriasis</td><td rowspan="1" colspan="1">Depression, IgM-&#954; monoclonal gammopathy of undetermined significance, palatal squamous cell carcinoma</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Topical therapy, systemic corticosteroids, methotrexate, brodalumab</td><td rowspan="1" colspan="1">Skin lesions almost resolved after 3&#160;weeks, leaving psoriatic onychopathy</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Pagliara<xref rid="cit0028" ref-type="bibr">28</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Plaque psoriasis</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Topical therapy, adalimumab</td><td rowspan="1" colspan="1">Lesions almost resolved after 1 month</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Adalimumab, secukinumab, brodalumab</td><td rowspan="1" colspan="1">Lesions almost resolved after 1 month</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Adalimumab</td><td rowspan="1" colspan="1">Lesions improved after 1 month</td><td rowspan="1" colspan="1">NA</td></tr><tr><td colspan="9" rowspan="1"><bold>Brodalumab: IL-17RA</bold></td></tr><tr><td rowspan="1" colspan="1">Milani-Nejad<xref rid="cit0029" ref-type="bibr">29</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">20 years</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">UV-B phototherapy, methotrexate, cyclosporine, acitretin, apremilast, adalimumab, infliximab, secukinumab, ixekizumab, ustekinumab, guselkumab</td><td rowspan="1" colspan="1">Skin lesions improved and almost complete resolved after 6 months</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Passante<xref rid="cit0030" ref-type="bibr">30</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">23 years</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Topical therapy, systemic corticosteroids, methotrexate, cyclosporine</td><td rowspan="1" colspan="1">Lesions completely resolved after 2&#160;weeks</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Bardazzi<xref rid="cit0031" ref-type="bibr">31</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6 months</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No joint involvement</td><td rowspan="1" colspan="1">Topical therapy, systemic anti-bacterial and anti-fungal therapy, acitretin, adalimumab, secukinumab</td><td rowspan="1" colspan="1">Lesions completely resolved after 4&#160;weeks, and maintained remission over 12 months</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Guerra<xref rid="cit0016" ref-type="bibr">16</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Methotrexate, acitretin</td><td rowspan="1" colspan="1">Lesions completely resolved after 12&#160;weeks</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Chularojanamontri<xref rid="cit0017" ref-type="bibr">17</xref></td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Symptoms improved in both patients, with 1 experience symptoms clearance</td><td rowspan="1" colspan="1">NA</td></tr><tr><td colspan="9" rowspan="1"><bold>Failure experience</bold></td></tr><tr><td colspan="9" rowspan="1"><bold>Ixekizumab: IL-17A</bold></td></tr><tr><td rowspan="1" colspan="1">Schmid<xref rid="cit0032" ref-type="bibr">32</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2 years</td><td rowspan="1" colspan="1">Psoriatic arthritis</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Joint erosion at toes</td><td rowspan="1" colspan="1">Topical therapy, methotrexate</td><td rowspan="1" colspan="1">Joint pain resolved within 1&#160;week, but skin and phalangeal lesions did not improve after 8 months (withdrawal)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6 years</td><td rowspan="1" colspan="1">Plaque psoriasis<break/>Psoriatic arthritis</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Topical therapy, systemic corticosteroids, methotrexate, cyclosporine, acitretin, apremilast, etanercept, infliximab, secukinumab, ustekinumab</td><td rowspan="1" colspan="1">Skin and nail lesions did not improve after 4 months</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Kromer<xref rid="cit0010" ref-type="bibr">10</xref></td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">No response to treatment in both patients<sup>c</sup></td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Zhang<xref rid="cit0009" ref-type="bibr">9</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">10 years</td><td rowspan="1" colspan="1">Annular pustular psoriasis</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">IL-36RN genetic mutation (c.115+6T&gt;C)</td><td rowspan="1" colspan="1">Cyclosporine, acitretin</td><td rowspan="1" colspan="1">Symptoms improved firstly, but acral swelling and lesions reappeared after 12&#160;weeks</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Chen<xref rid="cit0033" ref-type="bibr">33</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">9 months</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No associated or suspected pathogenic genetic mutation</td><td rowspan="1" colspan="1">Topical therapy, systemic corticosteroids</td><td rowspan="1" colspan="1">Symptoms did not improve after 2 months (withdrawal)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Wang<xref rid="cit0034" ref-type="bibr">34</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1 year</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Systemic corticosteroids, acitretin</td><td rowspan="1" colspan="1">Symptoms worsened after 14&#160;weeks (withdrawal)</td><td rowspan="1" colspan="1">No</td></tr><tr><td colspan="9" rowspan="1"><bold>Secukinumab: IL-17A</bold></td></tr><tr><td rowspan="1" colspan="1">Schmid<xref rid="cit0032" ref-type="bibr">32</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6 years</td><td rowspan="1" colspan="1">Plaque psoriasis<break/>Psoriatic arthritis</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Topical therapy, systemic corticosteroids, methotrexate, cyclosporine, acitretin, apremilast, etanercept, infliximab, ustekinumab</td><td rowspan="1" colspan="1">Joint symptoms alleviated, but skin and nail lesions did not improve after 6 months (withdrawal)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Bardazzi<xref rid="cit0031" ref-type="bibr">31</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6 months</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No joint involvement</td><td rowspan="1" colspan="1">Topical therapy, systemic anti-bacterial and anti-fungal therapy, acitretin, adalimumab</td><td rowspan="1" colspan="1">Symptoms partial improved after 4 months, but severe disease relapse occurred after 1 years</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Zhang<xref rid="cit0009" ref-type="bibr">9</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">12 years</td><td rowspan="1" colspan="1">Generalized pustular psoriasis</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Bone erosions at fingertips<break/>IL-36RN genetic mutation (c.115+6T&gt;C; c.227C&gt;T)</td><td rowspan="1" colspan="1">Systemic corticosteroids, thiamphenicol, acitretin</td><td rowspan="1" colspan="1">Skin lesion over the body disappeared, but acral swelling and lesions did not improve after 10 months</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&gt;10 years</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No osteolytic changes or joint deformities in radiological examination<break/>IL-36RN genetic mutation (c.115+6T&gt;C)</td><td rowspan="1" colspan="1">Traditional Chinese medicine, acitretin</td><td rowspan="1" colspan="1">Skin and nail lesions did not improve after 6 months</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Wen<xref rid="cit0035" ref-type="bibr">35</xref></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">16 years</td><td rowspan="1" colspan="1">Generalized pustular psoriasis</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Cyclosporine, acitretin, adalimumab</td><td rowspan="1" colspan="1">Skin lesions almost resolved, but nail lesions persisted after 3 months</td><td rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="t0001-fn1"><p><bold>Notes</bold>: <sup>#</sup>Laboratory examination mainly includes osteoarticular changes, and genetic mutations. <sup>a</sup>Though symptoms were improved in all 18 patients, with 1 patient unsatisfactory to treatment response (self-evaluation: ineffectiveness) and thus stopping treatment. <sup>b</sup>Though adverse events were reported, the specific manifestations were unknown and no patient discontinued treatment due to adverse events. <sup>c</sup>No response to treatment, including exacerbation of disease. <sup>d</sup>Data of 1 patient was missed.</p></fn></table-wrap-foot></table-wrap></p><p>In summary, IL-17-targeted therapy, vunakizumab in our case, is a promising alternative treatment for ACH, with advantages of high efficacy, favorable tolerability, and long dosing intervals. However, further studies with large sample sizes are necessary to confirm the efficacy and safety of IL-17-targeted therapy for ACH and to elucidate the potential factors affecting treatment outcomes.</p></sec></body><back><sec id="s0004"><title>Ethical Statement</title><p>The patient in this manuscript has given written informed consent to the publication of case details and any accompanying images. Institutional approval was not required to publish the case details.</p></sec><sec sec-type="COI-statement" id="s0005"><title>Disclosure</title><p>The authors declare that they have no conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chularojanamontri</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rattanakorn</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Julanon</surname><given-names>N</given-names></string-name>, et al. <article-title>Acrodermatitis continua of Hallopeau and generalised pustular psoriasis: should they be the same or different entities?</article-title><source><italic toggle="yes">Exp Dermatol</italic></source>. <year>2023</year>;<volume>32</volume>(<issue>8</issue>):<fpage>1235</fpage>&#8211;<lpage>1245</lpage>. doi:<pub-id pub-id-type="doi">10.1111/exd.14805</pub-id><pub-id pub-id-type="pmid">37057764</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Iorizzo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lipner</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Piraccini</surname><given-names>BM</given-names></string-name>, et al. <article-title>Acrodermatitis continua of Hallopeau&#8212;clinical review and proposed management algorithm</article-title>. <source><italic toggle="yes">J Am Acad Dermatol</italic></source>. <year>2025</year>;<volume>93</volume>(<issue>4</issue>):<fpage>1049</fpage>&#8211;<lpage>1057</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaad.2025.05.1438</pub-id><pub-id pub-id-type="pmid">40480373</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rosi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Fastame</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Di Cesare</surname><given-names>A</given-names></string-name>, et al. <article-title>Targeting IL-17A for the treatment of pustular psoriasis: a comprehensive review</article-title>. <source><italic toggle="yes">Expert Opin Biol Ther</italic></source>. <year>2022</year>;<volume>22</volume>(<issue>12</issue>):<fpage>1475</fpage>&#8211;<lpage>1487</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14712598.2022.2116978</pub-id><pub-id pub-id-type="pmid">35997143</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bi</surname><given-names>X</given-names></string-name>, et al. <article-title>Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled Phase 3 trial</article-title>. <source><italic toggle="yes">J Am Acad Dermatol</italic></source>. <year>2025</year>;<volume>92</volume>(<issue>1</issue>):<fpage>92</fpage>&#8211;<lpage>99</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaad.2024.09.031</pub-id><pub-id pub-id-type="pmid">39332633</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Diao</surname><given-names>Q</given-names></string-name>, et al. <article-title>A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis</article-title>. <source><italic toggle="yes">J Am Acad Dermatol</italic></source>. <year>2022</year>;<volume>87</volume>(<issue>1</issue>):<fpage>95</fpage>&#8211;<lpage>102</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaad.2022.01.005</pub-id><pub-id pub-id-type="pmid">35026342</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Keam</surname><given-names>SJ</given-names></string-name>. <article-title>Vunakizumab: first Approval</article-title>. <source><italic toggle="yes">Drugs</italic></source>. <year>2024</year>;<volume>84</volume>(<issue>11</issue>):<fpage>1481</fpage>&#8211;<lpage>1485</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40265-024-02110-8</pub-id><pub-id pub-id-type="pmid">39497021</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kim</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname><given-names>M</given-names></string-name>, et al. <article-title>Next-generation Anti-IL-17 agents for psoriatic disease: a pipeline review</article-title>. <source><italic toggle="yes">Am J Clin Dermatol</italic></source>. <year>2025</year>;<volume>26</volume>(<issue>3</issue>):<fpage>307</fpage>&#8211;<lpage>320</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40257-025-00928-w</pub-id><pub-id pub-id-type="pmid">39982633</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Passeron</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Perrot</surname><given-names>J-L</given-names></string-name>, <string-name name-style="western"><surname>Jullien</surname><given-names>D</given-names></string-name>, et al. <article-title>Treatment of severe palmoplantar pustular psoriasis with bimekizumab</article-title>. <source><italic toggle="yes">JAMA Dermatol</italic></source>. <year>2024</year>;<volume>160</volume>(<issue>2</issue>):<fpage>199</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamadermatol.2023.5051</pub-id><pub-id pub-id-type="pmid">38054800</pub-id><pub-id pub-id-type="pmcid">PMC10701662</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>C</given-names></string-name>, et al. <article-title>Adalimumab treatment for acrodermatitis continua of Hallopeau: three cases refractory to IL&#8208;17 inhibition</article-title>. <source><italic toggle="yes">J Dtsch Dermatol Ges</italic></source>. <year>2023</year>;<volume>21</volume>(<issue>7</issue>):<fpage>785</fpage>&#8211;<lpage>787</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ddg.15041</pub-id><pub-id pub-id-type="pmid">37186059</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kromer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Loewe</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Schaarschmidt</surname><given-names>ML</given-names></string-name>, et al. <article-title>Treatment of acrodermatitis continua of Hallopeau: a case series of 39 patients</article-title>. <source><italic toggle="yes">J Dermatol</italic></source>. <year>2020</year>;<volume>47</volume>(<issue>9</issue>):<fpage>989</fpage>&#8211;<lpage>997</lpage>. doi:<pub-id pub-id-type="doi">10.1111/1346-8138.15466</pub-id><pub-id pub-id-type="pmid">32632983</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pilz</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Roenneberg</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Biedermann</surname><given-names>T</given-names></string-name>, et al. <article-title>Ixekizumab for acrodermatitis continua</article-title>. <source><italic toggle="yes">J Dtsch Dermatol Ges</italic></source>. <year>2018</year>;<volume>16</volume>(<issue>7</issue>):<fpage>907</fpage>&#8211;<lpage>910</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ddg.13568</pub-id><pub-id pub-id-type="pmid">29927543</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Miller</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Holland</surname><given-names>TE</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>DJ</given-names></string-name>. <article-title>Treatment of acrodermatitis continua of hallopeau with ixekizumab</article-title>. <source><italic toggle="yes">J Dermatological Treat</italic></source>. <year>2019</year>;<volume>32</volume>(<issue>1</issue>):<fpage>117</fpage>&#8211;<lpage>119</lpage>. doi:<pub-id pub-id-type="doi">10.1080/09546634.2019.1628170</pub-id><pub-id pub-id-type="pmid">31184530</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Battista</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Guerrasio</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>De Fata Salvatores</surname><given-names>G</given-names></string-name>, et al. <article-title>Acrodermatitis continua of Hallopeau successfully treated with ixekizumab: a case report</article-title>. <source><italic toggle="yes">Dermatol Ther</italic></source>. <year>2022</year>;<volume>35</volume>(<issue>5</issue>). doi:<pub-id pub-id-type="doi">10.1111/dth.15383</pub-id><pub-id pub-id-type="pmcid">PMC9287084</pub-id><pub-id pub-id-type="pmid">35174591</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gargiulo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Toso</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ibba</surname><given-names>L</given-names></string-name>, et al. <article-title>Biologics for the treatment of severe acrodermatitis continua of hallopeau: report of two cases successfully treated with ixekizumab and ustekinumab</article-title>. <source><italic toggle="yes">Dermatol Pract Conceptual</italic></source>. <year>2023</year>:<fpage>e2023103</fpage>. doi:<pub-id pub-id-type="doi">10.5826/dpc.1302a103</pub-id>.<pub-id pub-id-type="pmcid">PMC10188160</pub-id><pub-id pub-id-type="pmid">37196286</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Xia</surname><given-names>RY</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>DD</given-names></string-name>, et al. <article-title>Ixekizumab for the treatment of acrodermatitis continua of hallopeau and inverse psoriasis</article-title>. <source><italic toggle="yes">Ind J Dermatol</italic></source>. <year>2023</year>;<volume>68</volume>(<issue>2</issue>):<fpage>234</fpage>. doi:<pub-id pub-id-type="doi">10.4103/ijd.ijd_884_22</pub-id><pub-id pub-id-type="pmcid">PMC10238979</pub-id><pub-id pub-id-type="pmid">37275799</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Guerra</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rosi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Scandagli</surname><given-names>I</given-names></string-name>, et al. <article-title>Anti-Interleukin-17s for successful management of pustular psoriasis</article-title>. <source><italic toggle="yes">Cytokine</italic></source>. <year>2023</year>;<volume>171</volume>:<fpage>156353</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cyto.2023.156353</pub-id><pub-id pub-id-type="pmid">37672865</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chularojanamontri</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Silpa&#8208;Archa</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pattamadilok</surname><given-names>B</given-names></string-name>, et al. <article-title>A retrospective analysis of 65 patients with acrodermatitis continua of Hallopeau</article-title>. <source><italic toggle="yes">Exp Dermatol</italic></source>. <year>2024</year>;<volume>33</volume>(<issue>3</issue>). doi:<pub-id pub-id-type="doi">10.1111/exd.15055</pub-id><pub-id pub-id-type="pmid">38519437</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yuan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>Y</given-names></string-name>, et al. <article-title>Acrodermatitis continua of hallopeau: aggravating factors and treatment outcomes of 96 patients</article-title>. <source><italic toggle="yes">J Dermatological Treat</italic></source>. <year>2024</year>;<volume>35</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.1080/09546634.2024.2434098</pub-id><pub-id pub-id-type="pmid">39608017</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Baron</surname><given-names>JA</given-names></string-name>. <article-title>Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab</article-title>. <source><italic toggle="yes">JAAD Case Rep</italic></source>. <year>2017</year>;<volume>3</volume>(<issue>3</issue>):<fpage>215</fpage>&#8211;<lpage>218</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jdcr.2017.02.016</pub-id><pub-id pub-id-type="pmid">28443313</pub-id><pub-id pub-id-type="pmcid">PMC5394207</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Muggli</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Maul</surname><given-names>J-T</given-names></string-name>, <string-name name-style="western"><surname>Anzengruber</surname><given-names>F</given-names></string-name>, et al. <article-title>Secukinumab for acrodermatitis continua of hallopeau</article-title>. <source><italic toggle="yes">JAMA Dermatol</italic></source>. <year>2017</year>;<volume>153</volume>(<issue>4</issue>):<fpage>336</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamadermatol.2016.5059</pub-id><pub-id pub-id-type="pmid">28122071</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Balestri</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rech</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tasin</surname><given-names>L</given-names></string-name>, et al. <article-title>Acrodermatitis continua of Hallopeau successfully treated with secukinumab</article-title>. <source><italic toggle="yes">J Dermatological Treat</italic></source>. <year>2018</year>;<volume>29</volume>(<issue>sup1</issue>):<fpage>3</fpage>&#8211;<lpage>5</lpage>. doi:<pub-id pub-id-type="doi">10.1080/09546634.2018.1527993</pub-id><pub-id pub-id-type="pmid">30246571</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Khosravi-Hafshejani</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dutz</surname><given-names>JP</given-names></string-name>. <article-title>Acrodermatitis continua of hallopeau with psoriatic arthritis</article-title>. <source><italic toggle="yes">J Rheumatol</italic></source>. <year>2019</year>;<volume>46</volume>(<issue>4</issue>):<fpage>437</fpage>&#8211;<lpage>438</lpage>. doi:<pub-id pub-id-type="doi">10.3899/jrheum.180086</pub-id><pub-id pub-id-type="pmid">30936225</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Galluzzo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Adamio</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Teoli</surname><given-names>M</given-names></string-name>, et al. <article-title>Biologic therapy for acrodermatitis continua of Hallopeau: successful treatment with secukinumab and review of the literature</article-title>. <source><italic toggle="yes">Dermatol Ther</italic></source>. <year>2019</year>;<volume>32</volume>(<issue>3</issue>). doi:<pub-id pub-id-type="doi">10.1111/dth.12899</pub-id><pub-id pub-id-type="pmcid">PMC6618131</pub-id><pub-id pub-id-type="pmid">30969010</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Smirnova</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Vertieva</surname><given-names>EY</given-names></string-name>, <string-name name-style="western"><surname>Olisova</surname><given-names>OY</given-names></string-name>, et al. <article-title>Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau</article-title>. <source><italic toggle="yes">Biologics</italic></source>. <year>2019</year>;<volume>13</volume>:<fpage>83</fpage>&#8211;<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.2147/btt.S199100</pub-id><pub-id pub-id-type="pmid">31190732</pub-id><pub-id pub-id-type="pmcid">PMC6535620</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cirone</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Lovegrove</surname><given-names>FE</given-names></string-name>. <article-title>Acrodermatitis continua of Hallopeau successfully treated with bimekizumab: a case report</article-title>. <source><italic toggle="yes">SAGE Open Med Case Rep</italic></source>. <year>2023</year>;<volume>11</volume>. doi:<pub-id pub-id-type="doi">10.1177/2050313x231160937</pub-id>.<pub-id pub-id-type="pmcid">PMC10034280</pub-id><pub-id pub-id-type="pmid">36968989</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yoshikawa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Takeichi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fukaura</surname><given-names>R</given-names></string-name>, et al. <article-title>Generalized acrodermatitis continua of Hallopeau with an IL36RN variant successfully treated with bimekizumab</article-title>. <source><italic toggle="yes">J Dermatol</italic></source>. <year>2024</year>;<volume>51</volume>(<issue>12</issue>). doi:<pub-id pub-id-type="doi">10.1111/1346-8138.17370</pub-id><pub-id pub-id-type="pmid">38995198</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Garc&#237;a-Rodr&#237;guez</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Salleras-Redonnet</surname><given-names>M</given-names></string-name>. <article-title>Plaque psoriasis, generalized pustular psoriasis, palmoplantar pustulosis, and acrodermatitis continua of Hallopeau successfully treated with bimekizumab: a promising therapeutic approach</article-title>. <source><italic toggle="yes">Eur J Dermatol</italic></source>. <year>2024</year>;<volume>34</volume>(<issue>4</issue>):<fpage>448</fpage>&#8211;<lpage>449</lpage>. doi:<pub-id pub-id-type="doi">10.1684/ejd.2024.4751</pub-id><pub-id pub-id-type="pmid">39193691</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pagliara</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bardazzi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Sacchelli</surname><given-names>L</given-names></string-name>, et al. <article-title>Acrodermatitis continua of hallopeau successfully treated with bimekizumab</article-title>. <source><italic toggle="yes">Dermatol Pract Conceptual</italic></source>. <year>2024</year>;<volume>14</volume>(<issue>4</issue>):<fpage>e2024279</fpage>. doi:<pub-id pub-id-type="doi">10.5826/dpc.1404a279</pub-id><pub-id pub-id-type="pmcid">PMC11620191</pub-id><pub-id pub-id-type="pmid">39652926</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Milani-Nejad</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kaffenberger</surname><given-names>J</given-names></string-name>. <article-title>Treatment of recalcitrant acrodermatitis continua of hallopeau with brodalumab</article-title>. <source><italic toggle="yes">J Drugs Dermatol</italic></source>. <year>2019</year>;<volume>18</volume>(<issue>10</issue>):<fpage>1047</fpage>.<pub-id pub-id-type="pmid">31603633</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Passante</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dastoli</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nistic&#242;</surname><given-names>SP</given-names></string-name>, et al. <article-title>Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: a case report</article-title>. <source><italic toggle="yes">Dermatol Ther</italic></source>. <year>2019</year>;<volume>33</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.1111/dth.13170</pub-id><pub-id pub-id-type="pmid">31762153</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bardazzi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Di Altobrando</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lacava</surname><given-names>R</given-names></string-name>. <article-title>Brodalumab in the treatment of recalcitrant acrodermatitis continua of Hallopeau</article-title>. <source><italic toggle="yes">Dermatol Ther</italic></source>. <year>2020</year>;<volume>33</volume>(<issue>6</issue>). doi:<pub-id pub-id-type="doi">10.1111/dth.14301</pub-id><pub-id pub-id-type="pmid">32920959</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Schmid</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mohr</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sch&#246;n</surname><given-names>MP</given-names></string-name>, et al. <article-title>Two cases of acrodermatitis continua suppurativa (Hallopeau&#8217;s disease) treated with IL&#8208;17A inhibitors</article-title>. <source><italic toggle="yes">J Dtsch Dermatol Ges</italic></source>. <year>2019</year>;<volume>17</volume>(<issue>6</issue>):<fpage>643</fpage>&#8211;<lpage>645</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ddg.13857</pub-id><pub-id pub-id-type="pmid">31241836</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>L</given-names></string-name>, et al. <article-title>Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib</article-title>. <source><italic toggle="yes">Eur J Dermatol</italic></source>. <year>2023</year>;<volume>33</volume>(<issue>2</issue>):<fpage>182</fpage>&#8211;<lpage>183</lpage>. doi:<pub-id pub-id-type="doi">10.1684/ejd.2023.4461</pub-id><pub-id pub-id-type="pmid">37431132</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>Y</given-names></string-name>, et al. <article-title>Local injection of micro&#8208;dose guselkumab for acrodermatitis continua of Hallopeau after failure of systemic ixekizumab treatment</article-title>. <source><italic toggle="yes">Int J Dermatol</italic></source>. <year>2024</year>;<volume>63</volume>(<issue>4</issue>):<fpage>547</fpage>&#8211;<lpage>548</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ijd.17036</pub-id><pub-id pub-id-type="pmid">38228398</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, et al. <article-title>Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report</article-title>. <source><italic toggle="yes">Front Immunol</italic></source>. <year>2024</year>;<volume>15</volume>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2024.1338285</pub-id><pub-id pub-id-type="pmcid">PMC10920288</pub-id><pub-id pub-id-type="pmid">38464535</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>